Corvus Pharmaceu Financials
This page shows Corvus Pharmaceu (CRVS) financial statements, including the income statement, balance sheet, cash flow statement, and key financial ratios. View 12 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).
Corvus is functioning as a cash-burning R&D enterprise, with equity financing repeatedly used to rebuild liquidity rather than fund expansion.
FY2025's narrower net loss to-$15.3M looks better on the surface, but operating loss widened to-$43.0M . With operating cash outflow also deeper than the prior year at-$32.8M , the accounting result improved while the underlying cash cost of running the business worsened, implying help from items outside the core expense base rather than a genuine move toward self-funding.
Financing cash inflow of
The burn is operating, not capital-intensive: capital spending was only
Financial Health Signals
Based on FY2025 annual data, averaged across the last 3 years for performance metrics (most-recent year weighted highest). How this score is calculated →
Health score ≠ stock price. This rates the quality of Corvus Pharmaceu's business: profitability, growth, balance sheet strength. It doesn't tell you whether the stock is a good buy at today's price. Not financial advice. Use it alongside valuation analysis and your own research.
Corvus Pharmaceu carries a low D/E ratio of 0.16, meaning only $0.16 of long-term debt for every $1 of shareholders' equity. This conservative leverage earns a score of 99/100, indicating a strong balance sheet with room for future borrowing.
With a current ratio of 6.21, Corvus Pharmaceu holds $6.21 in current assets for every $1 of short-term obligations. This comfortable liquidity earns a score of 100/100.
Corvus Pharmaceu generates a -25.0% ROE, indicating limited profit relative to shareholders' investment. This results in a returns score of 0/100. This is up from -191.3% the prior year.
Corvus Pharmaceu passes 2 of 9 financial strength tests. 1 of 4 profitability signals pass, 1 of 3 leverage/liquidity signals pass.
For every $1 of reported earnings, Corvus Pharmaceu generates $2.14 in operating cash flow (-$32.8M OCF vs -$15.3M net income). This low ratio suggests earnings are primarily driven by accounting accruals rather than cash generation, which may not be sustainable.
Key Financial Metrics
Earnings & Revenue
Corvus Pharmaceu's EBITDA was -$42.9M in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization. This represents a decrease of 56.1% from the prior year.
Corvus Pharmaceu reported -$15.3M in net income in fiscal year 2025. This represents an increase of 75.4% from the prior year.
Corvus Pharmaceu earned $-0.53 per diluted share (EPS) in fiscal year 2025. This represents an increase of 48.0% from the prior year.
Cash & Balance Sheet
Corvus Pharmaceu generated -$33.0M in free cash flow in fiscal year 2025, representing cash available after capex.
Corvus Pharmaceu held $4.6M in cash against $0 in long-term debt as of fiscal year 2025.
Corvus Pharmaceu had 75M shares outstanding in fiscal year 2025. This represents an increase of 10.0% from the prior year.
Margins & Returns
Corvus Pharmaceu's ROE was -25.0% in fiscal year 2025, measuring profit generated per dollar of shareholder equity. This is up 166.3 percentage points from the prior year.
Capital Allocation
Corvus Pharmaceu invested $33.7M in research and development in fiscal year 2025. This represents an increase of 73.9% from the prior year.
Corvus Pharmaceu invested $174K in capex in fiscal year 2025, funding long-term assets and infrastructure.
CRVS Income Statement
| Metric | Q1'26 | Q4'25 | Q3'25 | Q2'25 | Q1'25 | Q4'24 | Q3'24 | Q2'24 |
|---|---|---|---|---|---|---|---|---|
| Revenue | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Cost of Revenue | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Gross Profit | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| R&D Expenses | $11.2M | N/A | $8.5M+7.4% | $7.9M+5.6% | $7.5M | N/A | $5.2M+26.9% | $4.1M |
| SG&A Expenses | $3.7M | N/A | $2.1M-11.3% | $2.4M-3.3% | $2.5M | N/A | $2.0M+11.6% | $1.8M |
| Operating Income | -$14.9M | N/A | -$10.6M-3.0% | -$10.3M-3.4% | -$9.9M | N/A | -$7.3M-22.2% | -$5.9M |
| Interest Expense | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Income Tax | $0 | N/A | N/A | N/A | $0 | N/A | N/A | N/A |
| Net Income | -$13.7M | N/A | -$10.2M-27.0% | -$8.0M-152.6% | $15.2M | N/A | -$40.2M-843.6% | -$4.3M |
| EPS (Diluted) | $-0.15 | N/A | $-0.12-20.0% | $-0.10+23.1% | $-0.13 | N/A | $-0.60-757.1% | $-0.07 |
CRVS Balance Sheet
| Metric | Q1'26 | Q4'25 | Q3'25 | Q2'25 | Q1'25 | Q4'24 | Q3'24 | Q2'24 |
|---|---|---|---|---|---|---|---|---|
| Total Assets | $253.2M+256.0% | $71.1M-11.6% | $80.5M-10.0% | $89.5M+50.5% | $59.4M-13.7% | $68.9M+17.2% | $58.8M-8.9% | $64.6M |
| Current Assets | $239.9M+312.2% | $58.2M-13.0% | $66.9M-11.7% | $75.8M+66.6% | $45.5M-16.4% | $54.4M+26.8% | $42.9M-11.1% | $48.3M |
| Cash & Equivalents | $40.1M+776.4% | $4.6M+59.6% | $2.9M-80.5% | $14.7M+193.9% | $5.0M-42.8% | $8.7M+86.8% | $4.7M-68.5% | $14.8M |
| Inventory | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Accounts Receivable | $43K+16.2% | $37K+15.6% | $32K-62.8% | $86K+8.9% | $79K+5.3% | $75K+7.1% | $70K+100.0% | $35K |
| Goodwill | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Total Liabilities | $12.5M+26.2% | $9.9M+13.9% | $8.7M-5.7% | $9.2M-8.7% | $10.1M-72.2% | $36.3M-21.7% | $46.4M+248.0% | $13.3M |
| Current Liabilities | $12.1M+29.1% | $9.4M+16.2% | $8.1M-5.1% | $8.5M-8.3% | $9.3M-73.8% | $35.4M-23.7% | $46.4M+248.0% | $13.3M |
| Long-Term Debt | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Total Equity | $240.7M+293.2% | $61.2M-14.7% | $71.8M-10.5% | $80.2M+62.7% | $49.3M+51.5% | $32.6M+162.5% | $12.4M-75.8% | $51.2M |
| Retained Earnings | -$426.0M-3.3% | -$412.3M-3.1% | -$400.0M-2.6% | -$389.8M-2.1% | -$381.8M+3.8% | -$397.0M-3.1% | -$384.9M-11.7% | -$344.7M |
CRVS Cash Flow Statement
| Metric | Q1'26 | Q4'25 | Q3'25 | Q2'25 | Q1'25 | Q4'24 | Q3'24 | Q2'24 |
|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | -$10.4M-12.9% | -$9.2M+3.9% | -$9.6M-65.6% | -$5.8M+30.1% | -$8.3M+2.4% | -$8.5M-33.9% | -$6.3M-15.3% | -$5.5M |
| Capital Expenditures | $91K+264.0% | $25K | $0-100.0% | $113K+213.9% | $36K | N/A | N/A | N/A |
| Free Cash Flow | -$10.5M-13.6% | -$9.2M+3.7% | -$9.6M-62.4% | -$5.9M+29.0% | -$8.3M | N/A | N/A | N/A |
| Investing Cash Flow | -$144.8M-1431.3% | $10.9M+515.6% | -$2.6M+87.1% | -$20.3M-578.5% | $4.2M+169.8% | -$6.1M-56.4% | -$3.9M+77.8% | -$17.5M |
| Financing Cash Flow | $190.7M+953630.0% | $20K-94.4% | $360K-99.0% | $35.8M+12720.8% | $279K-98.5% | $18.6M+37116.0% | $50K | N/A |
| Dividends Paid | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Share Buybacks | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
CRVS Financial Ratios
| Metric | Q1'26 | Q4'25 | Q3'25 | Q2'25 | Q1'25 | Q4'24 | Q3'24 | Q2'24 |
|---|---|---|---|---|---|---|---|---|
| Gross Margin | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Operating Margin | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Net Margin | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Return on Equity | -5.7% | N/A | -14.1%-4.2pp | -10.0%-40.8pp | 30.8% | N/A | -324.1%-315.8pp | -8.3% |
| Return on Assets | -5.4% | N/A | -12.6%-3.7pp | -8.9%-34.5pp | 25.6% | N/A | -68.4%-61.8pp | -6.6% |
| Current Ratio | 19.81+13.6 | 6.21-2.1 | 8.29-0.6 | 8.91+4.0 | 4.90+3.4 | 1.54+0.6 | 0.92-2.7 | 3.62 |
| Debt-to-Equity | 0.05-0.1 | 0.16+0.0 | 0.120.0 | 0.12-0.1 | 0.20-0.9 | 1.12-2.6 | 3.74+3.5 | 0.26 |
| FCF Margin | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
Similar Companies
Frequently Asked Questions
Is Corvus Pharmaceu profitable?
No, Corvus Pharmaceu (CRVS) reported a net income of -$15.3M in fiscal year 2025.
What is Corvus Pharmaceu's EBITDA?
Corvus Pharmaceu (CRVS) had EBITDA of -$42.9M in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization.
What is Corvus Pharmaceu's return on equity (ROE)?
Corvus Pharmaceu (CRVS) has a return on equity of -25.0% for fiscal year 2025, measuring how efficiently the company generates profit from shareholder equity.
What is Corvus Pharmaceu's free cash flow?
Corvus Pharmaceu (CRVS) generated -$33.0M in free cash flow during fiscal year 2025. Free cash flow represents the cash a company generates after accounting for capital expenditures, and is widely used to assess financial flexibility and shareholder value.
What is Corvus Pharmaceu's operating cash flow?
Corvus Pharmaceu (CRVS) generated -$32.8M in operating cash flow during fiscal year 2025, representing cash generated from core business activities.
What are Corvus Pharmaceu's total assets?
Corvus Pharmaceu (CRVS) had $71.1M in total assets as of fiscal year 2025, including both current and long-term assets.
What are Corvus Pharmaceu's capital expenditures?
Corvus Pharmaceu (CRVS) invested $174K in capital expenditures during fiscal year 2025, funding long-term assets and infrastructure.
How much does Corvus Pharmaceu spend on research and development?
Corvus Pharmaceu (CRVS) invested $33.7M in research and development during fiscal year 2025.
What is Corvus Pharmaceu's current ratio?
Corvus Pharmaceu (CRVS) had a current ratio of 6.21 as of fiscal year 2025, which is generally considered healthy.
What is Corvus Pharmaceu's debt-to-equity ratio?
Corvus Pharmaceu (CRVS) had a debt-to-equity ratio of 0.16 as of fiscal year 2025, measuring the company's financial leverage by comparing total debt to shareholder equity.
What is Corvus Pharmaceu's return on assets (ROA)?
Corvus Pharmaceu (CRVS) had a return on assets of -21.5% for fiscal year 2025, measuring how efficiently the company uses its assets to generate profit.
What is Corvus Pharmaceu's cash runway?
Based on fiscal year 2025 data, Corvus Pharmaceu (CRVS) had $4.6M in cash against an annual operating cash burn of $32.8M. This gives an estimated cash runway of approximately 2 months at the current burn rate. Cash runway measures how long a company can continue operating before running out of cash, assuming no additional funding.
What is Corvus Pharmaceu's Piotroski F-Score?
Corvus Pharmaceu (CRVS) has a Piotroski F-Score of 2 out of 9, indicating weak financial health. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7 to 9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.
Are Corvus Pharmaceu's earnings high quality?
Corvus Pharmaceu (CRVS) has an earnings quality ratio of 2.14x, considered low quality (accrual-driven). This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.
How financially healthy is Corvus Pharmaceu?
Corvus Pharmaceu (CRVS) scores 33 out of 100 on our Financial Profile, indicating weak overall financial health. This composite score evaluates six dimensions: profitability (operating margin), revenue growth, leverage (debt-to-equity), liquidity (current ratio), cash flow quality (free cash flow margin), and shareholder returns (return on equity). Each dimension is normalized against standard financial benchmarks. Learn more in our complete guide to financial health indicators.